Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
- Address
- lock Available on a paid plan
Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
The Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania is a leading academic medical center conducting advanced clinical research across multiple therapeutic areas. The institution demonstrates particular strength in oncology research, with extensive expertise in both hematologic malignancies and solid tumors, including breast cancer, lung cancer, colorectal cancer, and bladder cancer. The center actively participates in cutting-edge immunotherapy trials and novel targeted therapy studies.
- Comprehensive oncology trials including breast cancer, lung cancer, lymphomas, and leukemias with focus on precision medicine approaches
- Immunological and autoimmune disorders encompassing multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, and rare conditions like myelin oligodendrocyte glycoprotein antibody-associated disease
- Dermatological conditions including psoriasis, vitiligo, hidradenitis suppurativa, and acne vulgaris
- Hematologic disorders and transplantation research, particularly in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and graft-versus-host disease
The institution's research portfolio reflects a commitment to translational medicine, conducting both early-phase dose-finding studies and large-scale Phase 3 comparative effectiveness trials. Particular emphasis is placed on biosimilar research, antibody-drug conjugates, and novel immunomodulatory agents. The center also contributes to cardiovascular research, respiratory disease trials including COPD, and rare disease investigations such as hereditary angioedema, hypereosinophilic syndrome, and systemic mastocytosis, demonstrating its comprehensive approach to advancing medical knowledge across diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 22 therapeutic areas and 15 of 408 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 394 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 97 by active trials.
lock +96 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Incyte Corp.13trials
lock +50 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
lock Showing 1 of 300 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis | Cogent Biosciences Inc. | Phase II | Not Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 408 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 20 | Unknown | 2017-10-02 | 2026-07-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.